Switzer Daily
19 May 2021
The IIR Pharma & Biotech Index performed well in April, up 6.2% Month-on-Month (MoM). This was above the ASX All Ordinaries Accumulation Index and the ASX Small Ordinaries Accumulation Index which were up 3.9% and 5.0% MoM, respectively.
Of the 140 companies in the IIR Pharma & Biotech Index, only 38 companies have a negative share price return over the 12-months to 30 April 2021 and 48 companies have a share price return of 100% or more.
ADO makes top 10
Anteotech Ltd (ASX: ADO) made its way into the top 10 constituents in April after the share price increased 74% for the month. The market cap of ADO has increased from $37.8 m to $815.3 m over the 12-months to April-end. We note that post month-end, the share price has weakened on the back of a capital raising at a significant discount.
Australia
Melbourne
Victoria
United-kingdom
Robert-cooke
Stephen-gourlay
Heramed-limited
Actinogen-medical-limited
Optiscan-imaging-limited
Joondalup-health-campus
Anteotech-ltd
Imugene-limited